ARS Pharma Reports Q1 2026 Earnings

ARS Pharma (SPRY) reported $22.7 million in total revenue for Q1 2026, with U.S. net product revenue from neffy reaching $17.5 million. The company noted a threefold increase in prescriptions year-over-year and is seeing improved market dynamics including better payer access.

By Motley Fool Transcribing, The Motley Fool Mon, May 18, 2026 at 4:27 PM GMT+3 30 min read · Yahoo Finance · May 18, 2026, 13:27 UTC

ARS Pharma Reports Q1 2026 Earnings

Tickers: $SPRY

Topics: epinephrine treatment pharmaceuticals revenue growth

Read the full article at Yahoo Finance

More World news

Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC
Zoom Ventures Invests in Medaica to Advance AI-Powered Virtual Healthcare Seeking Alpha · November 12, 2026, 13:40 UTC
Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC